Merck received FDA approval expanding Welireg (belzutifan) to a broader set of kidney cancer patients in combination with Eisai’s Lenvima (lenvatinib). The approval targets patients with advanced renal cell carcinoma meeting specified criteria. The update reflects Merck’s ongoing strategy to broaden label coverage beyond initial indications and to deepen adoption of HIF-2α inhibition in combination regimens. For oncology investors and procurement teams, combination approvals can quickly shift competitive dynamics across standard-of-care settings when follow-on reimbursement and guideline inclusion accelerate.